NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/11/2025
Back to search
Official data from USPTO
SYN-NAT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
03/11/2025
Trademark type
Combined
Nice classes
5
Filing date
05/12/2020
Registration date
03/11/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/11/2025
Last transaction
03/11/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/22/2023
First use in commerce
04/12/2024
Drawing code
5
Owner type
99
Owner location
Changsha, Hunan, CN
Examiner
HAYS, CANDACE W
Law office
M10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of designed letters "SYN-NAT".
Holders and representatives
Holders
Medoncare Pharmaceutical Co., Ltd.
Representatives
Timothy T. Wang NI, WANG & MASSAND, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Tonics of medicinesmedicinal tea; Medicines for human purposes in the form of effervescent tabletschewable tablet and chewing gum for use in preventing prostatitisbenign prostatic hyperplasiaurinary tract infectiongynecological inflammationgastrointestinal disease; Medicines for human purposes in the form of effervescent tabletschewable tablet and chewing gum for use in blood sugar regulationliver protectionas antioxidantsanti-hyperlipidemiaanti-agingantineoplastic and antiviral agents for medical use; Medicines for human purposesmedicines for the treatment of gastrointestinal diseaseskin diseasecardiovascular diseasegoutasthmanasitisprostatic cancerleukemiamelanomabrain gliomacolon cancercervical cancerthyroid cancerkidney cancerstomach cancer and lung cancerhepatitis Bhepatitis CAIDS and influenzaprostatitisbenign prostatic hyperplasia and gynecological inflammationdiabetessleep disorder and rheumatoid arthritis; Medicinal drinks; Capsules sold empty for pharmaceuticals; Pharmaceutical preparations for the treatment of gastrointestinal diseaseskin diseasecardiovascular diseasegoutasthmanasitisprostatic cancerleukemiamelanomabrain gliomacolon cancercervical cancerthyroid cancerkidney cancerstomach cancer and lung cancerhepatitis Bhepatitis CAIDS and influenzaprostatitisbenign prostatic hyperplasia and gynecological inflammationdiabetessleep disorder and rheumatoid arthritis; Chemico-pharmaceutical preparations for tumor-suppression and antiviral treatment; Trochestablets for use in tumor-suppressionas antivirals and for the treatment of chronic gastrointestinal disease; Tinctura in the nature of medicinal herb extracts; Herbs for medicinal purposes; Nutritional supplements; dietetic foods adapted for medical usedietetic drinksdietetic crackersdietetic sugar for medical usedietetic sugar substitutes for medical use; Dietary and nutritional supplements; Dietary food supplements; Dietary supplemental drinks; Dietary supplements; Dietetic beverages adapted for medical use; Dietetic foods adapted for medical purposes; Dietetic foods and beverages adapted for medical use; Nutraceuticals for use as a dietary supplement; Nutritional supplements in the form of capsulestabletscapletspowdersyrupsgummies and gels; Sanitizing preparations for commercial use
Publications
History of USPTO decisions and trademark events.
36 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
03/11/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/15/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/15/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/14/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/14/2025
IUAF
USE AMENDMENT FILED
12/03/2024
EISU
TEAS STATEMENT OF USE RECEIVED
12/03/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/02/2024
PUBO
PUBLISHED FOR OPPOSITION
04/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/13/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/29/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
08/29/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
03/01/2023
DOCK
ASSIGNED TO EXAMINER
01/17/2023
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
09/01/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
03/01/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
08/28/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/17/2021
GNSL
LETTER OF SUSPENSION E-MAILED
02/17/2021
CNSL
SUSPENSION LETTER WRITTEN
02/17/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/16/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/16/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/26/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/26/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/26/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/16/2020
GNRT
NON-FINAL ACTION E-MAILED
08/16/2020
CNRT
NON-FINAL ACTION WRITTEN
08/16/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/15/2020
GNSL
LETTER OF SUSPENSION E-MAILED
08/15/2020
CNSL
SUSPENSION LETTER WRITTEN
08/15/2020
DOCK
ASSIGNED TO EXAMINER
08/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/26/2020
NWAP
NEW APPLICATION ENTERED
05/15/2020
Continuous trademark protection
Get notified about every new filing that threatens SYN-NAT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.